SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
SYRS
Delisted
SYRS was delisted on the 19th of March, 2025.
12 hedge funds and large institutions have $207M invested in Syros Pharmaceuticals, Inc. Common Stock in 2016 Q2 according to their latest regulatory filings, with 12 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Holders
12
Holders Change
+12
Holders Change %
–
% of All Funds
0.32%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
%
% of All Funds
0.03%
New
12
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
Top Sellers
No sellers this quarter
| Name | Market Value | Shares |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
|
FVFIGP
1
Flagship Ventures Fund IV General Partner
Cambridge,
Massachusetts
| $87.2M | 4,806,656 | +4,806,656 | New |
|
|
DM
2
Deerfield Management
New York
| $38M | 2,095,220 | +2,095,220 | New |
|
3
Fidelity Investments
Boston,
Massachusetts
| $37.8M | 3,027,285 | +3,027,285 | New |
|
|
AC
4
Aisling Capital
New York
| $16.5M | 908,565 | +908,565 | New |
|
|
RG
5
Redmile Group
San Francisco,
California
| $15.1M | 946,182 | +946,182 | New |
|
|
BBA
6
Baker Bros. Advisors
New York
| $3.71M | 204,465 | +204,465 | New |
|
|
EAM
7
Eventide Asset Management
Boston,
Massachusetts
| $2.72M | 150,000 | +150,000 | New |
|
|
FCMI
8
Foresite Capital Management III
Larkspur,
California
| $2.72M | 150,000 | +150,000 | New |
|
9
Alyeska Investment Group
Chicago,
Illinois
| $1.27M | 70,000 | +70,000 | New |
|
|
CC
10
Casdin Capital
New York
| $908K | 50,000 | +50,000 | New |
|
|
WMSA
11
Weiss Multi-Strategy Advisers
New York
| $832K | 45,857 | +45,857 | New |
|
12
Goldman Sachs
New York
| $363K | 20,000 | +20,000 | New |
|